Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.

Name: Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
Author: Davies, Andrew

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. — المؤلف: Davies, Andrew — The Lancet. Oncology 20200615

المؤلف: Davies, Andrew
النشر: The Lancet. Oncology 20200615
الوصف: 649-662 p.
الموضوعات: Adult؛ Aged؛ Aged, 80 and over؛ Antineoplastic Combined Chemotherapy Protocols؛ Biomarkers, Tumor؛ Bortezomib؛ Cyclophosphamide؛ Disease Progression